Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase EARLY_PHASE1 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Sarcoma 3Breast 3Tumor-Agnostic 2Head & Neck 2Genitourinary 2CNS 2Plasma cell 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 140Lenalidomide 60Bortezomib 56Calcium Dobesilate 48Melphalan 44carfilzomib 40pomalidomide 39Cyclophosphamide 38daratumumab 27belantamab mafodotin 22ixazomib 19Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 16fludarabine 16dexamethasone acetate 14Bendamustine Hydrochloride 14Whole-Body Irradiation 13Filgrastim 13dexamethasone 21-phosphate 12Tacrolimus 12venetoclax 11auricularum 11Prednisone 11selinexor 10liposomal doxorubicin 10iberdomide 10Mycophenolic Acid 10isatuximab 9Cyclosporine 9pembrolizumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Fluorodeoxyglucose F18 × Plasma cell × Clear all
NCT07463807 2026-05-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
162 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡